InflaRx N.V.
IFRXInflaRx N.V. in brief
InflaRx N.V. is a listed company in the Biotechnology industry, based in Germany. Its market value was $301 M on 1 August 2026, which makes it the 14,740th largest listed company in the world and the 208th largest in Germany on this site. In the year to December 2025 it had sales of $0 M and a net loss of $51 M. Niels Riedemann is its chief executive. Its shares trade under the symbol IFRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
InflaRx N.V. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed InflaRx N.V.Formerly Fireman B.V..
- 🔔Initial public offering as Fireman B.V.Final prospectus filed with the SEC on 8 November 2017; shares registered for exchange trading on 7 November 2017.
Events of InflaRx N.V. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Germany: #374 (Jan 2020) · #348 (Jan 2021) · #331 (Jan 2022) · #313 (Dec 2022) · #272 (Jul 2023) · #327 (Jan 2024) · #4 (Mar 2026) · #210 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 10033.3×
- Price / book
- 35.7×
- Free cash flow yield
- -13.3%
- Net margin (TTM)
- -171533.3%
- Operating margin
- —
- Return on equity
- -610.4%
- Liabilities / assets
- 24.7%
- Revenue growth
- -83.3%
- R&D / revenue
- 96700.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | -83.3% | — | $-51M | -171533.3% |
| Dec 2024 | $0M | +157.1% | — | $-50M | -27694.4% |
| Dec 2023 | $0M | — | $-49M | $-46M | -65885.7% |
| Dec 2022 | — | — | $-34M | $-31M | — |
| Dec 2021 | — | — | $-56M | $-54M | — |
| Dec 2020 | — | — | — | $-39M | — |
| Dec 2019 | — | — | — | $-60M | — |
| Dec 2018 | — | — | — | $-35M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-40M | $0M | $-40M | $-0.77 | — |
| Dec 2024 | $-53M | $0M | $-53M | $-0.84 | — |
| Dec 2023 | $-41M | $0M | $-41M | $-0.84 | — |
| Dec 2022 | $-35M | $0M | $-36M | $-0.70 | — |
| Dec 2021 | $-47M | $0M | $-47M | $-1.30 | — |
| Dec 2020 | $-42M | $0M | $-42M | $-1.44 | — |
| Dec 2019 | $-48M | — | — | — | — |
| Dec 2018 | $-25M | — | — | — | — |
SEC filings
- Nov 6, 20266-KReport of foreign issuer
- Nov 3, 20266-KReport of foreign issuer
- Nov 3, 20266-KReport of foreign issuer
- Oct 22, 20266-KReport of foreign issuer
- Aug 6, 20266-KReport of foreign issuer
- Jun 30, 20266-KReport of foreign issuer
- May 7, 20266-KReport of foreign issuer
- May 6, 20266-KReport of foreign issuer
- May 6, 20266-KReport of foreign issuer
- May 4, 20266-KReport of foreign issuer
- Apr 28, 20266-KReport of foreign issuer
- Apr 23, 20266-KReport of foreign issuer
Official filings of InflaRx N.V. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- —
- Net income
- $-51 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $65 M
- Total liabilities
- $16 M
- Total equity
- $8 M
As of December-2025
Top 64 institutional investors in InflaRx N.V.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Montanova Capital, LLC | 22,933,910 | 0 (0.00%) | $41 M | Nov 16, 2026 |
| 2 | TCG Crossover Management, LLC | 14,500,000 | 0 (0.00%) | $26 M | Nov 16, 2026 |
| 3 | FMR LLC | 9,305,472 | +1,142,131 (+13.99%) | $17 M | Nov 10, 2026 |
| 4 | Commodore Capital LP | 9,268,220 | +1,968,220 (+26.96%) | $17 M | Nov 16, 2026 |
| 5 | Spruce Street Capital LP | 6,086,170 | +733,972 (+13.71%) | $11 M | Nov 13, 2026 |
| 6 | 683 Capital Management, LLC | 4,690,000 | -375,000 (-7.40%) | $8 M | Nov 16, 2026 |
| 7 | Farallon Capital Management, L.L.C. | 3,310,000 | -15,000 (-0.45%) | $6 M | Nov 16, 2026 |
| 8 | Ameriprise Financial Inc | 3,093,460 | +520,661 (+20.24%) | $6 M | Nov 16, 2026 |
| 9 | Great Point Partners LLC | 3,046,557 | 0 (0.00%) | $5 M | Nov 16, 2026 |
| 10 | ADAR1 Capital Management, LLC | 3,000,000 | 0 (0.00%) | $5 M | Nov 16, 2026 |
| 11 | Kalehua Capital Management LLC | 2,921,095 | -2,874,443 (-49.60%) | $5 M | Nov 13, 2026 |
| 12 | Nantahala Capital Management, LLC | 2,693,948 | New | $5 M | Nov 13, 2026 |
| 13 | Stempoint Capital LP | 2,485,233 | -743,022 (-23.02%) | $4 M | Nov 16, 2026 |
| 14 | Woodline Partners LP | 2,105,486 | 0 (0.00%) | $4 M | Nov 16, 2026 |
| 15 | Eversept Partners, LP | 1,355,382 | +51,313 (+3.93%) | $2 M | Nov 16, 2026 |
| 16 | Millennium Management LLC | 1,027,158 | +460,109 (+81.14%) | $2 M | Nov 16, 2026 |
| 17 | BNP Paribas Financial Markets | 1,000,311 | +868,473 (+658.74%) | $2 M | Nov 12, 2026 |
| 18 | Marshall Wace, LLP | 995,319 | +284,023 (+39.93%) | $2 M | Nov 13, 2026 |
| 19 | DCF Advisers, LLC | 975,000 | +746,500 (+326.70%) | $2 M | Nov 4, 2026 |
| 20 | Jefferies Financial Group Inc. | 717,074 | -58,275 (-7.52%) | $1 M | Nov 5, 2026 |
| 21 | Citadel Advisors LLC | 714,492 | +575,202 (+412.95%) | $1 M | Nov 16, 2026 |
| 22 | Morgan Stanley | 559,830 | -355,784 (-38.86%) | $1 M | Nov 13, 2026 |
| 23 | T3 Companies, LLC | 440,000 | +108,986 (+32.92%) | $1 M | Oct 22, 2026 |
| 24 | Point72 Asset Management, L.P. | 433,893 | New | $1 M | Nov 16, 2026 |
| 25 | UBS Group AG | 383,288 | +304,155 (+384.36%) | $1 M | Nov 10, 2026 |
All 64 institutional investors: 26 to 64, with who bought and sold →
Mutual funds holding InflaRx N.V.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 3.29 M | $6 M | 1.9% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 3.20 M | $5 M | 1.8% | 0.25% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 1.68 M | $3 M | 0.95% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 376,105 | $1 M | 0.21% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 43,672 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 23,128 | $0 M | 0.01% | <0.01% | −13% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,363 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: InflaRx N.V.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 9,915 shares at $1.55
- : 172,480 shares at $1.59
- : 276 shares at $1.89
- : 869 shares at $2.08
- : 13,699 shares at $2.06
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
InflaRx N.V. scorecard#
Passes 0 of the 6 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
Growth0 of 2
Profitability0 of 3
Financial health0 of 1
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
InflaRx N.V.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.0 | 0.2 | 0.1 | — | — | — | — | — | — | — | |
| Cost of revenue | 7.3 | 3.3 | 0.5 | — | — | — | — | — | — | — | |
| Gross profit | −7.2 | −3.2 | −0.5 | — | — | — | — | −38 | −20 | −7.1 | |
| Research and development | 26 | 35 | 41 | 38 | 36 | 26 | 45 | 25r | 14r | 5.3 | |
| Selling, general and administrative | 0.0 | 0.0 | 0.1 | 0.1r | 0.1r | 8.5 | 13 | 13r | 5.1r | 1.8 | |
| Selling and marketing | 4.5 | 6.8 | 4.0 | — | — | — | — | — | — | — | |
| Total costs and expenses | — | — | — | 52 | 48 | 34 | 57 | 38 | 20 | — | |
| Operating income | — | — | −45 | −32 | −48 | — | — | — | — | — | |
| Interest and finance income | 1.8 | 3.2 | 3.8 | 0.6 | 0.1 | 0.9 | 2.8r | 2.2r | 0.1r | 0.0 | |
| Interest expense and finance costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0r | 0.0r | −0.0r | 0r | 4.9r | 2.0 | |
| Provision for credit losses | — | — | — | −4.2 | −6.8 | 6.0 | — | — | — | — | |
| Income before tax | −46 | −46 | −43 | −29 | −46 | −34 | −53 | −30r | −24r | −8.9 | |
| Income tax | 0.0 | 0.0 | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |
| Income from continuing operations | — | — | — | — | — | — | — | — | −19 | −6.9 | |
| Net income including minority interests | −46 | −46 | −43 | −29 | −46 | −34 | −53 | −30r | −24r | −8.9 | |
| Earnings per share, basic | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 | -1.26 | — | — | — | — | |
| Earnings per share, diluted | -0.68 | -0.78 | -0.78 | -0.67 | -1.10 | -1.26 | — | — | — | — | |
| Shares, weighted average (basic) | 67 | 59 | 55 | 44 | 42 | 27 | 26 | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 42 | 27 | 26 | 25r | 9.4r | 0.0 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 16 | 18 | 13 | 16 | 26 | 26 | 33 | 55r | 123r | 29r | |
| Inventory | — | 6.9 | 11 | — | — | — | — | — | — | — | |
| Other current assets | 3.3 | 5.1 | 4.0r | 14 | 11 | 3.7 | — | — | — | — | |
| Current assets | 54 | 72 | 109r | 97 | 96 | 86 | 119 | 158r | 124 | 29 | |
| Property, plant and equipment | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.6r | 0.6r | 0.2 | — | |
| Right-of-use (leased) assets | 0.9 | 0.8 | 1.1 | 1.3 | 1.4 | 0.5 | 0.8 | — | — | — | |
| Other intangible assets | — | — | — | 0.1 | 0.2 | 0.4 | 0.5 | 0.2r | 0.0 | 0.0 | |
| Non-current assets | 1.6 | 4.4 | 11 | 5.0 | 29r | 1.9 | 2.6 | 1.1r | 0.2 | 0.1 | |
| Total assets | 55 | 76 | 120r | 102 | 125 | 88 | 122 | 159r | 124 | 30 | |
| Accounts payable | 5.4 | 11 | 12 | 5.0 | 8.6 | 8.3 | 12 | 6.7r | 4.5r | 1.5 | |
| Current liabilities | 13 | 14 | 17r | 13 | 19 | 10 | 14 | 7.8r | 4.8r | 1.7 | |
| Lease liabilities (non-current) | 0.6 | 0.4 | 0.7 | 1.0 | 1.1 | 0.2 | 0.3 | 0 | — | — | |
| Non-current liabilities | 0.7 | 0.4 | 0.8 | 1.0 | 1.1 | 0.3 | 0.4 | 0.1r | 0.0 | 53 | |
| Total liabilities | 14 | 15 | 18 | 14 | 20 | 10 | 14 | 7.8r | 4.8 | — | |
| Retained earnings | −378 | −332 | −286 | −243 | −214 | −168 | −134 | −81r | −51 | −27 | |
| Shareholders' equity | 7.2 | 7.4 | 7.4 | 7.3 | 3.1 | — | — | — | — | — | |
| Total equity | 42 | 61 | 103 | 88 | 105 | 78 | 107 | 151r | 119r | −26r | |
| Total liabilities and equity | 55 | 76 | 120 | 102 | 125 | 88 | 122 | 159r | 124 | 30 | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 4.4 | 4.1 | 3.4 | 6.0 | 4.3 | 1.1 | — | — | — | — | |
| Cash from operating activities | −35 | −49 | −38 | −34 | −40r | −37 | −43 | −22r | −12r | −5.0 | |
| Capital expenditure | −0.1 | −0.0 | −0.1 | −0.2 | −0.0 | −0.1 | — | — | — | — | |
| Intangible assets bought | — | — | — | — | −0.0 | −0.1r | −0.6r | −0.8r | −0.1r | −0.1 | |
| Cash from investing activities | 3.2 | 52 | −18 | 19 | −26 | 21 | 20 | −99r | −0.2r | −0.1 | |
| Debt repaid | −0.4 | −0.4 | −0.4 | −0.4 | −0.4r | −0.4r | −0.3r | 0 | 0 | — | |
| Shares issued | 23 | 1.1 | 56 | 2.3 | 65 | 9.8 | — | — | — | — | |
| Cash from financing activities | 33 | 0.4 | 53 | 1.9 | 62 | 9.2 | −0.3 | 50r | 109r | 31 | |
| Exchange-rate effect on cash | −3.6 | 1.4 | −1.0 | 2.5 | 4.6 | −1.2 | 0.9 | 3.5r | −2.3r | 0.0 | |
| Change in cash | 1.2 | 4.2 | −2.5 | −12 | −4.3 | −6.0 | −23r | −71r | 94r | 26 | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F/A | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How InflaRx N.V. compares in Biotechnology
- Market cap$301 M · higher than 51% of 726
- Revenue$0 M · higher than 13% of 647
- Revenue growth-83.3% · higher than 5% of 438
- Price / book35.7× · lower than 5% of 534
- FCF yield-13.3% · higher than 52% of 449
- 🇮🇪 Amarin Corporation$297 M
- 🇺🇸 Vogenx, Inc.$296 M
- 🇺🇸 Yarrow Bioscience, Inc.$307 M
- 🇺🇸 Benitec Biopharma Inc.$307 M
- 🇺🇸 Alector, Inc.$293 M
- 🇺🇸 Prelude Therapeutics Incorporated$311 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| InflaRx N.V.🇩🇪 | $301 M | — | — | -83.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 21, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at InflaRx N.V.? Verify and update this profile — free
Show InflaRx N.V.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.